Brief: Oncternal Therapeutics Presents Plans For Registrational Phase 3 Study Evaluating Zilovertamab In Combination With Ibrutinib
10/06/2022 14:12
June 10 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS PRESENTS RATIONALE AND PLANS FOR
ITS
REGISTRATIONAL PHASE 3 STUDY EVALUATING ZILOVERTAMAB IN
COMBINATION WITH IBRUTINIB AT THE EHA 2022 CONGRESS
Source text for Eikon: ID:nGNX5wtGdP
Further company coverage: ONCT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;